Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
Chung-Han LeeRobert J MotzerHamid EmamekhooMarc MatranaIvor J PercentJames J HsiehArif HussainUlka VaishampayanSandy LiuSteven McCuneVijay PatelMontaser ShaheenJohanna BendellAlice C FanBenjamin A GartrellOscar B GoodmanPetros G NikolinakosArash Rezazadeh KalebastyYousef ZakhariaZhentao ZhangHema ParmarLalith AkellaKeith OrfordNizar M TannirPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
TelaE was well tolerated and improved PFS versus PboE in patients with mRCC previously treated with TKIs and checkpoint inhibitors.